Just spitballin’ here …
Dear Business-Builder,
OK, so I lied.
I tried to comment on all your great comments about the direct mail package I asked you to critique last week; I really did!
Unfortunately, I’ve been busier than a one-armed paper hanger for the past three weeks – so if you’re feeling a bit neglected …
It’s The Redhead’s fault.
Well, come to think of it, it’s not just Wendy’s fault – my clients have had me slaving over a hot keyboard 12 hours a day and the ResponseInk staff has needed a little TLC here and there, too.
So, please accept their sincerest apologies for my neglect. I’ll try to make it up to you today – with my own take on the promotion we looked at last week.
If you’d like to open it and read along, click here …
Now right up front, let me say that, while I know the publisher of the newsletter promoted in this direct mail package well – and respect the hell out of him — I have no idea who actually wrote this promotion. So what I’m about to say is about as objective as I’m capable of being.
The way I see it, suggesting possible improvements in a promotion should never be seen as a reproach of the copywriter who created it. Too many hands are involved in the final product — including the company owner, the editor of the newsletter, the marketing people and of course, the regulators whose cautions and prohibitions help shape everything we do.
Our mission here is not to criticize, nor to inflate our own egos by slamming another writer, but to practice the gentle, cerebral, creative art of critiquing copy; to ask ourselves, “How would I try to beat this control? What test panels would I suggest if this was my client?”
In other words, we’re just doing a little spit-ballin’ here.
That said, I think this promo has a lot of great things going for it. It is, obviously, a promotion for a financial newsletter. If the marketing people did their job (and considering what direct mail costs these days, I’m sure they did!), it was sent to prospects who currently subscribe to other people’s financial newsletters.
So we know that the target market is highly-qualified ROWM (rich old white men) and a smattering of ROWW (women) and ROPOBSIOEG (“rich old people of both sexes in other ethnic groups”) who invest a substantial amount of time and money in the process of making their investment decisions.
Put simply, stock junkies. Folks who gladly, even eagerly PAY for stock tips.
So the overall concept — the story of a super-cheap stock concealing a big, BIG secret – is a powerful one. Not only that, it’s tried and true. Investment newsletter publishers have been using this approach with great success for decades.
So here’s what I’m thinking as I read this promo …
In case you can’t get the PDF of the promo I’m talking about, it leads with news about a company that has a new product that replaces insulin. Instead of injecting themselves five times per day, this new product lets diabetics get by on just one injection every three months.
The headline on the outer envelope and sales letter – “17-cent-a-share company with an “almost cure” for diabetes” — is a solid one.
The writer calls out his investor audience – the phrase “17 cent-a-share company” immediately communicates that this is about a stock.
The mention of diabetes is strong, too – just about everyone knows that diabetes is pandemic around the world today.
And the “almost cure” part is intriguing enough to make me want to read the deck copy, below the headline.
I do think, however, that more could be done to romance the opportunity this promotion presents in the headline, deck and opening copy.
For my money, headlining the stock’s price — the “17-cent company” phrase in the head – could be making the prospect work too hard in the 3.2 seconds he spends scanning the envelope teaser before deciding whether or not he’ll open and read the letter inside.
It doesn’t connect the dots for him. There are hundreds-of-thousands of cheap stocks out there. And as every investor knows, “cheapness” does not equal “goodness.”
To the contrary: When a stock is this cheap, it begs the question “Why?” There must be a reason why investors won’t touch this stock even with an 11-foot pole (the poles reserved for touching things the ten-foot poles won’t reach).
To me, the real headline – the sizzle here — is the remarkable discovery that’s about to catapult this 17-cent company into the limelight.
After all: This company is about to give diabetics the opportunity to SKIP 449 out of every 450 injections they’re giving themselves now — cut the number of times they have to get pricked by 99.777778% — and presumably, cut the cost they pay for insulin injections by a comparable amount!
On a one-to-ten scale of the world’s most valuable companies, a 17-cent stock is pretty much a zero.
But THIS stock is about to go “from a zero to a hero” – from a penny stock that nobody’s heard of …
To the stock an elite handful of future gazillionaires will cite when they regale their grandbabies with the story of how they got rich.
From mere intrigue to guilty desire …
Now, if I told you I could name a stock that, unbeknownst to the vast majority of investors out there, was about to experience an historic, unprecedented, mind-boggling sales explosion …
If I also told you that stock was so cheap you could buy 1,000 shares for just $170 … or 10,000 shares for just $1,700 … or 100,000 shares for a measly $17,000 … or one-quarter million shares for just over $42,000 …
… Wouldn’t you want to know about it?
Holey Moley, Myrtle! Is this an IQ test? OF COURSE I want to know about it! Jeeze: Just tell me what I have to do! What disgusting, degrading (but possibly interesting) act do I have to perform to get you to whisper that sweet ticker symbol into my ear?!
If you tell me – and then prove — that the company is about to have a sales explosion the likes of which few companies but Microsoft and Apple have ever seen …
And then show me how similar sales explosions (are there any?) have caused other companies’ stock prices to explode ten times … twenty times … fifty times over …
And THEN tell me that I can damn-near corner the market in that stock for pocket change …
You’ve GOT me, baby!
Of course, to make this work, we’ll need a few more specifics; some data and reliable outside sources to back it up. (Where I can find them, they’re included below. Where I can’t, I made them up; just to demonstrate my thinking …)
Dimensionalizing the problem and the solution
According to the U.S. Centers for Disease Control, 10% of all Americans over the age of 20 have diabetes — more than 20 million people in all. Most have Type II diabetes and about 12% are now taking insulin. Worldwide, the Nobel Prize committee estimates that more than 300 million people will be diagnosed with the disease over the next few years.
If 12% of them wind up on insulin, this product will be a godsend to more than 36 million souls!
Now, since we don’t know which stock the copywriter’s talking about, we’ll have to do a little guesstimating to demonstrate the thought process here …
How much will this product cost per dose? The copy doesn’t say, so let’s guesstimate it at, say – what? … five bucks a shot?
The copy also does not say what the company’s current sales revenues are – but if the share sells for a mere 19 cents, I’d be willing to bet the company has almost no revenues. The new drug described in this letter is probably the company’s very first offering.
Nevertheless let’s be generous – and just for the sake of argument, let’s say this company’s revenues are now running at about $1 million per year.
Okay, so if 36 million diabetes sufferers ultimately wind up taking this new drug four times a year at $5 a dose (carry the one …) that would generate $720 million in sales revenues for the company.
Even if only half of the world’s diabetics wind up using this new product, the company stands to make $360 million per year.
Heck; even if only one-tenth of the world’s diabetics – just 3.6 million fortunate souls – begin taking this product four times per year – that’s $72 million per year: A whopping 72 times the company’s current sales revenues!
Why not do the real math with the real numbers and come up with a guesstimate on this stock’s potential? After all: A sales explosion that multiplies revenues 72 times over is a 7,100% increase!
Then, make a list of the greatest stock windfalls of all time – companies like Microsoft, Apple, Intel and others. What kind of sales increases (on a percentage basis) accompanied their rise to glory?
I’ll bet you that you’ll have to combine several of the greatest stock windfall stories of all time to come up with anything that comes close to a 7,100% sales increase!
Uh – oh … time for some more arithmetic …
Now, I have some questions.
How much does the average insulin injection cost? We actually called a pharmacy on this one. According to our local Dr. Feelgood, each injection costs an average of about $2.85 – and according to the copy, some diabetics need up to five injections per day.
Just for the sake of argument, though … let’s say the average diabetic gets just two injections per day. That’s $5.70 per day times 36 million diabetics worldwide.
What’d you come up with? My calculator says $205 million per day; $74.9 billion per year.
At the cost of $5 four times per year, this new drug would cut that cost to just $720 million, saving insurers 99% of what they now pay for every diabetes sufferer with a policy.
Their savings by moving their policyholders to this new drug adds up to a staggering $74.2 BILLION IN SAVINGS PER YEAR … every year … forever!
Let’s create a mania …
Given how much money this new drug can save them, don’t you think that the minute it’s approved in Russia, every government on the planet is going to fast-track their approval to make sure they get these savings, too?
Don’t you also think that every health insurer on the planet is going to demand that every doctor on the planet prescribe this drug and ONLY this drug to every diabetic on the planet?
I don’t know about you; but I see a stampede taking shape, here. This is NOT just about a drug being approved in far-away Russia – the fuse is being lit on an explosion of demand for this drug worldwide!
And also make this promotion more TOPICAL …
Let’s make this real: Health care reform is top of the news – and for that reason, it’s top of our prospects’ minds and they have very strong resident emotions concerning it.
The reason why health insurance is top of the news is that medical costs are exploding. But this drug could cut what diabetes costs by 99.7% (or whatever)!
Could it be that this company has single-handedly solved the health care crisis?
Could the argument be made that this one, new drug makes all the hoo-hah about national health care unnecessary?
What are you, crazy? That would be a BIG TIME squib move! You couldn’t make that case in a billion years!
Merely implying such a thing would lead any thinking person to conclude you’d lost your mind. Or worse – that you’re lying through your teeth just to make a sale.
But a rational, plausible and extremely persuasive argument could be made that this new drug is a huge breakthrough in the global war against soaring medical costs!
Plus, it will catch on like wildfire simply because thousands of VERY persuasive salesmen – governments, insurers and doctors worldwide — have a vested interest in promoting it.
Once it’s approved in Russia and fast-tracked by national drug agencies around the globe …
EVERY insurance company …
EVERY national health plan …
Will soon have no choice but to DEMAND that EVERY doctor prescribe it!
See how our lead is beginning to write itself?
We’ve outed some key potential elements of a killer deck and lead that suggest this is a stock on a hair trigger …
- This company’s new product lets patients SKIP 499 out of every 450 injections they’re getting now for Type II diabetes.
- 36 million diabetes sufferers would do almost anything to get it …
- The world’s largest health insurers – both private companies and major governments – NEED the $75.5 billion this product will save them every single year …
- In the next few weeks, a major world government will give it a green light — and when it does, Katie, bar the door!
- I’m looking for this pipsqueak of a company to experience a sale explosion of up to 7,100% — multiplying its stock’s value five times, ten times, maybe even 20 times over …
- But right now, until word gets out, this stock is yours for just 17 cents per share … 1,000 shares for just $170 … or 10,000 shares for just $1,700 … or 100,000 shares for a measly $17,000 …
- DETAILS INSIDE (or, in the case of the sales letter, “below.”)
So how would YOU write this headline, deck and lead? I know — let’s have a contest! (More on that in a moment.)
The headline
Just going through this thought process has suggested quite a few respectable headline idea starters …
There’s the “Zero to Hero” concept … an “investment IQ test” … the “better than Microsoft and Apple combined” idea …
There’s the “hair trigger stock” concept … the “36 million customers-in-waiting” thought … “The little stock with the BIG secret” occurred to me … even the startling, probably-too-abrasive idea of toying with “Blood Money” as a part of the head (Get it? It’s a blood sugar miracle, you know?) zipped through my brain.
All are worth playing with; massaging into a strong headline idea – and maybe two or three of them would be worth a test.
And there’s also a completely different approach I might want to try as well …
Why not turn the whole rationale on its head?
What if, instead of using a greed lead (make a bundle with this cheap stock that has a secret) … why not test a fear-based lead?
Instead of focusing on a stock that’s set to soar, why test a panel in which the headline names a “Goliath” stock that this “David” of a company is about to crush?
Heck; most self-respecting investors own pharmaceutical companies – either directly or through mutual funds: Why not use the head and deck to warn investors about a company they probably already own – like Eli Lilly, for instance – one of the companies that’s getting richest selling insulin to the masses?
Heck: If this obscure little no-name, foreign drug company is about to make insulin obsolete (another headline idea!), it’s about to cost Lilly and other insulin manufacturers BILLIONS! Up to $74.2 billions! Per year!
I don’t care who you are; if your company suddenly loses that much money in revenues, your stock is going to crater.
If you owned Lilly – or shares of a mutual fund or pension plan that owned them – wouldn’t you risk getting a paper cut tearing the envelope open and then devour everything inside?
No, I’m not going to write a new lead for you …
So here’s the challenge: How would you use the thoughts and ideas in this article to write a control-whacking headline and deck for this promotion?
What new ideas do you have that are even better?
Just scroll down and type your inspired prose for the headline and deck into the box below (don’t copy and paste from Word; you’ll lose all your paragraph breaks).
Next Monday, I’ll pick my three favorites and the lucky winners will get a FREE copy of Steal These Secrets Volumes 1 & 2. Each volume is selling for $197 in our online store, so it should be ample incentive to do your best work.
Can’t wait to see what you come up with. Me? I’m gonna take a NAP!
Yours for Bigger Winners, More Often,
Clayton Makepeace
Publisher & Editor
THE TOTAL PACKAGE
P.S. About the Pub Note in our case study: Great, brilliant, perfect. No fooling around, straight to testimonials – and every one of them cites specific performance examples; how much money the editor of this service has made for his customers.
However, you should keep in mind that this promotion was clearly written before the FTC’s recent ruling on the use of testimonials.
Now, I’m no lawyer (I’ve often been called worse — but not much worse). But the way I understand it, that ruling, issued on the 5th of October, requires that in order to use testimonials citing specific performance, you must:
- Prove that your results were actually achieved and not just that subscribers claimed they achieved (which in this case, would require you to get a copy of actual brokerage statements documenting their profits from each customer cited), and ALSO …
- Prove that these results are typical – that in this case, your average subscriber does as well as those who provided the testimonials.
BTW: The Federal Trade Commission has also just issued new rules for online marketers – specifically, for affiliates who recommend other peoples’ products without disclosing that they’re being compensated for making the recommendation.
A smart person would jump over to FTC.gov and read up – or better yet, pay a real ambulance chaser to read the legalese for you and then tell you what it all means.
Looking for resources related to this article? Try some of these.
Looking for more of Clayton's articles? Check these out.
Looking for past issues of The Total Package? Click here for our archives.
23 Comments »
Join the Discussion!
Let us know what you think. Or ask us anything. Or offer your own sage advice.
The only rule: RESPECT THIS HOUSE! Postings that contain abusive language and/or personal attacks will be cheerfully VAPORIZED. One cross word and – POOF! – your well-thought-out post will be gone in a puff of smoke.
– Clayton
Comment by RAY EDWARDS — October 20, 2009 @ 11:42 am
“How ‘Blood Money’ Can Help Obama’s Health Care Plan …
By Up to $74.2 billions Per year!
(Curiosity, News subject awareness, Polarizing name-Obama)
Comment by John B — October 20, 2009 @ 7:32 pm
Ray Edwards Still Up To No Good…
Hi Clayton,
Just laughin’ at one of your ideas… Ha…Ha…Haaa,
…wait, still laughing…
Spitballin’ what a great way to look at all this critique stuff. Plus you remembered to sooth the wounds with kind, empathetic words to the nice folks who created the investment control.
I forgot to console them after I butchered that control.
Thanks for all your valuable free info.
Giddy-up,
John Babin
Comment by Nizom — October 21, 2009 @ 2:59 am
“A company with currently 17 cents-per-share stock and a sale explosion of up to 7,100%? You have to be kidding!”
Comment by Ronald Nzimora — October 21, 2009 @ 11:09 am
Hi Clayton,
Brilliant article.
I have a few ideas here, but i’m also borrowing from
your ideas…
My headline:
Foreign Drug Company Is About To Make Insulin Obsolete
- And Put Eli Lilly Out Of Business!
And if you act fast…you’ll grab a nice slice of this
company for only 17 cents per share
My Deck:
This company’s new product lets patients SKIP 499 out of every 450 injections they’re getting now for Type II diabetes…
36 million diabetes sufferers (in the US alone) will do
almost anything to lay their hands on it …
The world’s largest health insurers – both private companies and major governments – NEED the $75.5 billion this product will save them every single year and will clamour for it…
In the next few weeks, a major world government will give it a green light — and when it does, Katie, bar the door!
This virtually unknown company will almost certainly experience a sale explosion of up to 7,100% — multiplying its stock’s value five times, ten times, maybe even 20 times over …
But right now, until word gets out, this stock is yours for just 17 cents per share … 1,000 shares for just $170 … or 10,000 shares for just $1,700 … or 100,000 shares for a measly $17,000 …
DETAILS BELOW…
I hope i did this justice.
Ronald Nzimora
Comment by Emette Massey — October 21, 2009 @ 9:47 pm
Excellent post Clayton . . . not to mention mind bending and thought provoking. So I thought I’d chime in with my headline and deck idea . . .
THE HEALTH CARE SHOCK HEARD AROUND THE WORLD
* Tiny Asian Company patents new “almost-cure” for diabetes is closing in on final regulatory green light in Russia–the third largest diabetic population in the world!
* 36 MILLION American Diabetes suffers begging for an Insulin alternative!
* Drasticially cuts insulin injections from 2 to 5 times a day to just one every three months!
* Analysists predict a sale explosion –shares going to double or triple in a week.
* Read the Full Story Inside . . .
Warmly,
Emette
Comment by serrac — October 22, 2009 @ 4:50 am
HEADLINE:
Jane feels the pain and does it anyway - up to five times a day.
Subhead:
She’d be dead in 48 hours if she stopped.
Deck:
For Jane, like millions of other diabetics, needs her insulin shots just to stay alive.
Only one problem.
Her treatment regime is killing her anyway.
See, there’s no way a few daily jabs can replicate the miraculus control system a healthy body uses to keep sugar levels in check.
So these injections send her body on a roller-coaster-ride which only ends when it runs off the rails and kills her.
As she injects herself, her insulin levels soar far beyond the levels needed to deal with the sugar currently in her bloodstream.
So what happens to all that excess insulin in her system?
It gets to work attacking the walls of blood vessels everywhere in her body, causing (among other things…) arteriosclorosis and setting her up for a heart attack or stroke.
Things aren’t any better at the bottom of the ride either. Excess sugar in her blood wrecks her kidneys and destroys the blood vessels in her retinas. She will likely go blind in middle age.
Few diabetics live to a healthy old age on insulin injections.
But Jane is about to be thrown a lifeline.
A tiny biotech company has pioneered a treatment which wrests control of blood sugar from the syringe and hands it back to the body - where it belongs.
Their treatment is about to pass a major regulatory milestone.
When that happens this company is will depart on a ride of a different sort - more like a moon shot.
Millions of diabetics around the world will start SCREAMING for this lifesaver.
And those who get on board now will have a story to pass down their grandchildren and great-grandchildren - along with legendary profits.
Comment by Deb Day — October 22, 2009 @ 10:59 am
Headline:
IF YOU ARE COUNTING ON PHARMACEUTICAL STOCK FOR YOUR RETIREMENT PLAN…YOU COULD BE FLIPPING BURGERS AT
MC DONALDS.
Subhead:
Companies like Eli Lilly have been getting rich selling insulin to the 36 million diabetics whose lives depend on it. This little company will steal billions in sales as they make insulin as obsolete as cassette tapes.
Deck:
Health care reform is top priority right now. Medical costs are exploding. This new drug would save insurers 99% of what they now pay for every diabetes sufferer with a policy.
With that kind of savings-
EVERY insurance company…
EVERY national health plan…
Will soon have no choice but to DEMAND that EVERY doctor prescribe it!They can’t afford not to.
This obscure 17 cents a share,foreign drug company is about to cost big pharma BILLIONS in sales. To be exact $74.2 billion per year.
In the next few weeks a major world government will give it a green light–and when it does…
If you own pharmaceutical companies-either directly or through mutual funds:if your company suddenly loses that much money in revenue, your stock is going to crater.
Until word gets out, this stock is just 17 cents per share…1,000 shares for just $170…or 10,000 shares for just $1,700…or 100,000 shares for a measly $17,000…Cheap insurance against a retirement at McDonalds.
Details Inside
Comment by Tony Policci — October 22, 2009 @ 2:33 pm
“If I Paid You $7 For Every Dime You Gave Me…How Many Could You Scrounge Up?”
I’m only submitting a headline because I’m too busy working on a clients product launch, but a damned great newsletter Clayton.
Comment by Roy Furr — October 23, 2009 @ 7:20 am
Clayton,
Thanks for the newsletter — great insight into your crit process and how you think about improving packages.
Here’s my swing:
—
DIABETES PROFITS!
“I’ve just uncovered a breakthrough Diabetes treatment which makes insulin shots obsolete — it’s about to get the ‘go’ from regulators.”
“On approval, this tiny Asian pharmaceutical firm is positioned to siphon off $74.2 Billion in sales from Eli Lilly, Aventis, and Novo Nordisk. See inside for proof this could multiply revenue by as much as 7,100% — turning every $1,700 invested now into…”
Ching Tycangco, Editor
Asian Growth Stocks
—
Looking forward to seeing you at AWAI’s Bootcamp.
Roy
Comment by Tom Bell — October 23, 2009 @ 9:46 am
Hi Clayton! I write mainly for the web and had to look at a few of the responses to get a feel for what a “deck” was
Here we go…
If You’re Diabetic, Listen.
If You’re An Investor, Cheer!
Groundbreaking new product helps diabetics say goodby to painful, messy needles 99.5% of the time while causing saavy investors in the right place at the right time to make a KILLING.
Since you are smart enough to know a “win win” when you see it, Ill just skip to the facts:
* $75 BILLION in savings for GREEDY insurers.
* In The US alone, 36 million NEEDY diabetics.
* Major government slated for SPEEDY approval.
Ask your gut, the true expert, what happens when something this good, this helpful to so many people hits the market? what happens when a smart investor like you saw it coming and climbed aboard for the ride up of a lifetime!
Analists predict this stock, currently undervalued at only 17 cents will experience a rise in value of 5, 10 even 20 FOLD!
Now is the perfect time to a few hundred to a few thousand bucks into the bragging rights for having seen this one coming, for being the one who took ACTION on what we feel is the stock of the decade!
Be sure to look out for the specific benefits to diabetics and smart investors in the short letter below…
*****
Tom
Comment by Matthew — October 23, 2009 @ 11:40 am
When This 17-Cents-A-Share Company Puts Eli Lilly, And Other Big Names, Out Of The $74.2 Billion A Year Insulin Business…Will Your Portfolio Take A Hit?
One “little” company is about to hit the World’s 3rd largest Diabetes market (Russia) with a new “miracle” that all but eliminates the need for insulin. Instead of having to self-inject many times a day…life-long Diabetes sufferers will be able to treat themselves once every few months (no diabetes patient would pass on this amazing opportunity).
Imagine the frenzy that will sweep the trading floor when investors finally realize that this little gem of a company just put giant pharmas like Eli Lilly in the poor-house…I’m banking on the stock price to double or triple inside a week…are you going to be one of the lucky few cashing in on this new “medical miracle”?
Comment by Eric — October 23, 2009 @ 11:49 am
Monopoly Killer:
Company From Nowhere Poised To Knock Off Two Industry Titans And Pocket Billions In Blood Money
If there’s one thing investors love it’s being on the winning side of a monopoly. Let’s face it … it’s closest we’ll ever come to a sure thing — steady, predictable cash flow with minimal downside risk.
Now imagine you had a the market cornered on something people needed to buy EVERY DAY for their very survival?
Seeing some potential for HUGE profits here?
It’s no fantasy. Today the multi-billion dollar insulin market has just two major players — Novo Nordisk and Eli Lilly. And their products keep over 60 million diabetics alive worldwide.
These guys are simply monsters in their industry.
For years, they’ve exploited their monopolistic advantage and made investors fistfulls of money.
So you’re thinking, “Great! I’m ready to get in!”
Unfortunately, no. As they say, “timing is everything,” and this play is over. Jumping in now will likely spell disaster for your portfolio.
Why?
Because these two “bloodsport” champions are ready to fall.
Hard.
And that’s good news for you.
Because as lucrative as these two companies have been, their downfall is going to make all those past profits look like pocket change to those who get ahead of the curve on what’s to come.
We love monopolies, yes …
We like them even better when they come to an end.
Because there’s one thing more profitable than a monopoly–it’s being on the right side of it’s destruction.
Comment by Eric — October 23, 2009 @ 11:50 am
bah!
Change “it’s” to “its”. I know better than that.
Comment by Debra — October 23, 2009 @ 1:11 pm
Breakthrough Discovery Has Diabetics Dancing in the Streets and Investors Joining Them…
…Pioneering Asian company finds revolutionary treatment that reduces diabetic injections from up to 5X per day to just 1X every 3 months.
…Russia, the world’s 3rd largest diabetic market, is poised to be the first to get approval and access to this revolutionary treatment. Once approved, people will be flocking to Russia to get their hands on this revolutionary discovery.
…Diabetes is a major chronic disease afflicting an estimated 246 million people worldwide and growing…diabetics will be clamoring to get a breakthrough treatment that will reduce their number of daily insulin injections…the value of this company will skyrocket over night.
…With the current stock value at 17¢ a share and poised to explode, read on to learn how you can get a piece of this lucrative discovery…
Comment by Sid — October 23, 2009 @ 1:40 pm
Great Insights Clayton,
Here’s my idea to play to the “Hungry Crowd”
*******************************************************
Envelope Tease:
ARE YOU A RICH OLD WHITE GUY ?
The contents of this envelope can make you a LOT MORE RICH!
Note: INSIDER SECRETS: NOT JUST FOR RICH OLD WHITE
GUYS ANYMORE.
What ever your race, gender or current finances:
OPEN THIS NOW!
**********************************************************
Headline of Letter:
The Penny Stock That’s Poised to Make Microsoft and Apple seem like failures by comparison!
What if you were a diabetic? You may be one (the chances are good with 36,000,000 diabetics in the world and more everyday).
(The reader just thought about friends or family members that are diabetics)
That’s the huge size of this growing market for a product which is controlled by a small Asian firm currently trading at 17 Cents a share.
THE PRODUCT: A new drug that cuts the need for insulin by up to 99.78%. Just Imagine the savings in pain and money to millions and millions of sufferers! This product cuts the need from up to 5 injections a day to ___ every ___ months.
DO You see the potential for this product? (Reader thinks yes, but still may have doubts)
Talk about shooting fish in a barrel!
As every Experienced Investor knows
(Yes the reader thinks of him/herself as an experienced investor, right?)
opportunities just don’t come along everyday like this one. More like once or perhaps twice in a lifetime.
THE GOOD NEWS IS… IT GETS EVEN BETTER! This product has already been approved in Russia which means that the approval process will be put on the fast track by the rest of the world… which translates into an even more rapid rise in share prices.
But, what about companies like Eli Lilly who have been milking over 36 million diabetics in insulin sales because their lives depend on it? Won’t they try and stop this revolutionary product from coming to market?
Probably, but just think who will be on your side! The Health Insurance companies of the world along with the Goverment Health care systems of the world … That’s Who!
Who do think will win? The Insurance companies and the government health care systems of the world… THAT’s WHO!
You may want to sell Eli Lilly short when the timing is right and earn from both ends of the investment stick.
OK, By now you’re probably chomping at the bit to find out just how you can get in on the ground floor and learn all about this small Asian firm, I know I was when I first heard of this golden opportuity.
HERE’S HOW TO GET ALL THE SCOOP ON THE MOST REVOLUTIONARY OPPORTUNITY TO COME DOWN THE PIKE IN A LONG, LONG TIME !
Etc.
Thanks Clayton for the great exercise.
See you at Bootcamp in Del Rey Beach. I’ll be the oldest guy there unless you’re older than 68.
Sid
Comment by John B — October 24, 2009 @ 10:57 am
John Babin Official Entry johncharles65@yahoo.com
Do you secretly wish you had Super Powers over the Economy?
BABY 17 CENT SHARE STOCK FORECASTED TO GROW INTO 17 FOOT MONEY MONSTER.
REVEALED: a secret new ecomony for you to tap that is practically hidden from Wall Street fat cats.
* Pharmaceutical company makes a remarkable discovery allowing tens of millions of people a better solution to the huge insulin problem. The CDC has declared that some 20 million Americans alone have diabetes.
* Find out why diabetics in Russia are raving over this new “almost cure” and how this is sure to rake in the cash for you.
* Discover why this stock is quietly rumbling at a low 17 cents and how you will be given full access right now before the “herd” rushes in and tramples over you.
Dear Investor Friend,
My name goes before me. Many investors have a real sense of respect for me and my expertise in stocks.
Allow me to give you a list of my credentials to ease your skeptical mind. Plus, here’s what I’ve done for others just like you:
Comment by Sam — October 24, 2009 @ 4:14 pm
A dime…a nickel…two cents. A total of only 17 cents for a share in a company that has a unique diabetic drug.It delivers long-lasting insulin.1 shot every three months or more,instead of the 14-35 needles every week for the rest of a diabetic’s life. There are 9,500,615 insulin dependent Russians alone.
This drug is now undergoing its final test in Russia.
Your investment in this company will zoom after its approval.
So break the piggy bank and load up. Now. You will be funding your child’s future, and at the same time feel good about helping a small firm have more money to research cures for diabetes.
The 1 oz silver Panda coin gift: it’s worth far more than its value in silver - it’s a priceless charm. Whenever you invest in stocks rub it for good luck!
Comment by William Konupek — October 26, 2009 @ 12:36 am
Man lives after being shot 5 times in one day… And the ones responsible now stand to loose $74.2 billion dollars.
Could this be the future of a well known celebrity completely muffled by a foreign power.
Is it Ian Flemming’s new attempt at intrigue…
Or could it be that the drug of choice used by millions… is to become even more attractive and accessible… And at a cost that will defy common sense?
Reality check please…
You see… All three are partly true.
It appears that the face of a well known celebrity–Eli Lilly–is about to be muffled in the drug business by a foreign power… And at what cost… pennies on the dollar.
Now that my friends is Intrigue.
If an undisclosed manufacturer in Russia has its day, the face of insulin will be forever changed… Read More…
This is my attempt. I am merely a humble beginner.
I shall be a copywriter some day very soon.
Clayton you and many others have inspired this in me.
Thank you for all your help.
William Konupek
Comment by Jamie — October 26, 2009 @ 3:40 am
First time ever writing copy but I think its pretty fun. Here Goes..
—Start
NEWS FLASH: The Ruskies are about to save Obama’s neck and make you rich in the process.
A virtual unknown company is getting fast tracked by Russia to give diabetics patients the opportunity to SKIP 449 out of every 450 injections they’re giving themselves now. That’s a 99+% decrease!! INSANE.. I know but it actually gets better…
It is also going to save them $74 billion a year… that’s right BILLION not million and we are just talking existing patients here!!! The Noble Prize Committee estimates 300 million NEW PATIENTS worldwide in the next few years alone.
Ok, Ok, so their is a staggering amount of patients, it actually makes their lives better (so they will beat down their Docs door to get it), all the while saving them truckloads of money. I know… you have heard this story before, Massive Market, Brilliant Product, but all the value was gobbled up by Wall Street and now the stock costs a $150 a share because everyone watching CNN knows its the next Coca Cola.
This is where the story turns in your favor… no one has heard of it yet! The stock costs an embarrassing 17 cents… FOR REAL. When an opportunity like this comes knocking on your door I would RUN not walk for the chance to take this “Risk”. Even if I had to cut out the daily Starbucks for life just to get a shot at cashing in on this giant in the making.
This is like getting in on the ground floor of Microsoft or Apple. Except for one BIG difference Microsoft and Apple were even more “Risky” because they actually had to create the market. It seems obvious in hindsight but when they started they had no idea everyone in the known world would have a computer… but we KNOW 300 million people are about to become NEW patients.
So thank the Russians for more than just good Vodka and pounce on this opportunity while you can. Microsoft’s and Apple’s don’t come along everyday you know!!!
—-END
It would be cool to get some feedback!!!
Cheers
Comment by Jerry Y — October 26, 2009 @ 9:04 am
Here’s my entry…
**************************
“Turn $1,700 into $63,240… with This Undiscovered 17-Cent Stock? YEAH RIGHT!”
Think it’s impossible to make 3,720% profits on a stock? Well, it’s ALMOST impossible. But tell that to investors who made 4,650% on AOL… 4,980% on eBay… and 5,900% on Microsoft!
Of course, such stocks are like shooting stars. They’re rare — and the opportunity to “catch” them is fleeting. But I believe THIS little-known biotech company is the next “shooting star”, and here’s why:
This under-publicized company has the patent on a diabetes “almost cure” — a godsend to 29.5 million insulin-dependent diabetics worldwide. This “almost cure” allows diabetics to produce the insulin they need, WITHIN their own bodies.
This frees insulin-dependent diabetics from painful and expensive daily insulin injections. It also saves them (and their insurers) 98.9% of their treatment costs – which adds up to $74.2 BILLION per year!
So this tiny company is poised to corner the multi-billion dollar per year diabetic market worldwide… explode its share price… and make early-bird investors up to 37 times richer.
There’s a very good reason why most investors haven’t heard of this company. And this is precisely why the window of opportunity is still open. Read this urgent bulletin now for the full details…
**************************
Jerry
Comment by Rod Newbound, RN — October 26, 2009 @ 9:29 am
Big Pharma About to Take Blood Bath When World Governments Fast Track New Diabetic Wonder Drug
Tiny Russian Company Could Make Insulin Obsolete
Every day 35.9 diabetics worldwide are forced to take up to 5 doses of insulin to keep their blood sugar under control. Each dose costs $2.38. Estimated annual cost - $155.8 billion.
The World health Organization (WHO) estimates 135 million people suffer from diabetes worldwide and this number is expected to rise to 300 million by 2025. In the US alone diabetes costs $92 billion in direct medical costs every year. And the CDC estimates 135,000 new cases of diabetes a year. And 27.6 % will eventually need to take insulin daily. And up until now there has been no end in sight.
But a tiny Russian company has discovered a way to control diabetes without insulin. And when their new method of control is approved for treatment… worldwide governments will rush to release it to reduce the staggering cost of health care.
Act now to learn how you can invest in this Russian company for pennies. Details below.
Comment by Michelle B. Williams — October 26, 2009 @ 12:52 pm
Hi Clayton,
Give my best to the redhead, here’s my swing at it:
**************************
“Russian David Set To Knockout Two Needle Pushing Goliaths, In A Multi-Billion Dollar Battle Over Blood Money”
Sharp, inner circle investors, stand to make obscene profits just by moving swiftly to scoop up this little known
biotech stock, with a strange name.
If you missed out on the rare opportunities to make over 4,000% return on AOL… and eBay, listen closely because
the window to move on this is about to snap shut.
There is a tiny, biotech company in Russia that is about to change the global pharmaceutical landscape forever.
This company, whose name I can barely pronounce,is nailbiting close to releasing a game changer in the way that
diabetes is treated worldwide.
Their soon to be released, drug allows diabetics to produce their own insulin.
That means that there will no longer be any need for diabetic patients to suffer painful and expensive daily
insulin injections.
Imagine what this will do to improve the life of diabetic patients everywhere, while slashing the staggering
costs associated with their traditional, daily treatment regime of needles and insulin.
The stampede to get this drug will only be matched by the surge in their stock price.
When large fortunes are at stake, savvy investors, keep their cards close to their chest.
So you can be sure that you won’t hear much about this stock until after big returns have been pocketed by the
same small circle of investors.
You know those people who always seem two steps ahead of the rest of the market.
Today, anyone in the know, can pick up this stock for literally pennies on the dollar.
So the only question that remains, is “ Which end of the stampede do you want to be on?”
Read this urgent Special Report now for the full details…
**************************
Michelle
Comment by Shane Arthur — October 29, 2009 @ 10:31 am
There were several great submissions above. If I had more time I’d submit something along the lines of what Tom or Erik did.
However, I’ll go for quick shock value here. I don’t know the audience well enough, but this ought to get their attention enough to read the first sentence:
““““““““““““““““
PRICKS & STOCK PICKS!
How to get 99% less of them…
And earn 50-fold from them…
All for pennies on the dollar.
““““““““““““““““
Regards,
Shane